ArticleFrontiers in oncology2024
The role of radiotherapy in small cell lung cancer: a new paradigm for the radiation oncologist.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is an aggressive tumor that presents in most cases as a metastatic disease. The prognosis is poor, but the advent of immunotherapy has rekindled hopes for outcomes. Radiotherapy plays a crucial role in this oncological scenario, and there are still many open questions on the correct application of radiotherapy and its integration with chemotherapy and immunotherapy. These issues are of great interest to the oncology community; among these, in particular, there are the choice of optimal fractionation and total dose for thoracic radiotherapy in limited SCLC and its biological implications, the role of prophylactic cranial irradiation and thoracic consolidation in the context of modern treatments with chemoimmunotherapy in extensive SCLC, the role and indications of stereotactic radiotherapy in oligometastatic scenario and finally the complex clinical and multidisciplinary management of SCLC. This perspective article aims to describe the strengths and limitations of the role of radiotherapy in SCLC, highlighting the critical role of radiotherapy and the radiation oncologist, with the need to implement specific knowledge and skills on SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.